PQE Group Reports Solid Year-End Results, Strengthens Position through Innovation in Pharmaceuticals and Medical Devices
27.1.2026 15:00:00 CET | Business Wire | Press Release
2025 represented another successful year for PQE Group, a consulting firm in the Life Sciences industry based in Florence (Italy) that includes more than 2000 employees and 40+ offices worldwide. Recently named "Best Managed Company" by Deloitte Private for the sixth consecutive year, the Group achieved a rise in revenue, which reached € 105 millions in 2025, an increase of 7% compared to the €97,5M millions realized in 2024.
Founded by CEO Gilda D'Incerti in 1998, PQE Group is a women-owned company that has received numerous industry certifications, including ISO/IEC 27001, which is the world's best-known standard for information security, and ISO 9001, which focuses on quality management systems. To enhance its ongoing global expansion efforts, in 2025 PQE further expanded in the APAC Region, continued to strengthen its presence in North America, and established new offices in Latina, Italy and Copenhagen, Denmark. PQE also deepened its commitment to Artificial Intelligence (AI) in 2025, focusing heavily on PQE’s AI and Cybersecurity Services excellence and allocating significant resources to stay abreast of AI technological advancements, trends, and offerings in the Life Sciences industry.
In addition to receiving Deloitte Private’s Best Managed Company 2025 Award, PQE’s achievements and recognitions throughout the year included: Great Place to Work Certification for its US Subsidiary for the fourth consecutive year; Best Life Science Company in Maryland by Stellar Business Awards; Ecovadis Badge for Sustainability Excellence 2026; and recognition among the top 75 ESG performers at the Sustainability Award 2025, receiving the 2025 Sustainability Award Italy, which recognizes PQE’s commitment to ESG, the goals of which are published in its Sustainability Report each year, thereby disclosing detailed information on PQE’s sustainability strategy.
In 2025, PQE enhanced its already knowledgeable, professional SME staff by hiring additional senior level consultants and industry experts in numerous service areas, including the recent appointment of Francesco Minà as new Vice President Operations, who, after two decades spent working in the field of Automation and Operational Excellence for Johnson & Johnson, will now lead the service delivery of PQE Group at global level.
“2025 has been a positive year for PQE Group, a private company, made in Italy, with an international dimension,” said Gilda D’Incerti, PQE Group’s CEO & Founder. “This allows us to be in competition with the biggest consulting companies,” she continued, “and not only because of our global network and substantial number of highly specialized resources. By continuously monitoring industry trends and evolving technologies, we provide high-level solutions at competitive costs, pairing local responsiveness with global expertise, and we are quickly becoming one of the top worldwide consulting companies in the biopharmaceutical and medical device industries.”
As PQE continues to expand its global network, it is very committed to investing in expertise and knowledgeable professionals, delivering innovative and impactful solutions for its clients worldwide, and giving back through meaningful social responsibility initiatives— alongside an on-going commitment to patients’ safety and constant efforts to positively enhance the Life Science industry. On this note, the company is a proud member of the EU-funded Project-COMFORT Consortium that aims to transform healthcare through Patient Centric micro-Sampling (PCmS), a minimally invasive method for collecting and analyzing blood samples outside traditional clinical settings. For this effort, PQE is currently leading the “Work Package 7: Laying the Foundation for the Future”, to engage with the project’s audiences by sharing insights, updates, and outputs such as reports and publications.
About PQE Group
Established in Florence, Italy, in 1998, PQE Group is a woman-owned leading Life Science consulting firm, providing high-quality solutions in GCP, GLP, GMP, and GDP areas to both industry giants and small-mid-size businesses worldwide. With a focus on innovation, efficiency, and sustainability and with a global presence through its 40+ offices located around the world and 2000+ professional employees, PQE Group continues to set industry benchmarks and drive positive change in the Life Science sector. The Group's CEO & Founder, Gilda D'Incerti, has also launched ReSQ-UP, a groundbreaking initiative in the Clinical Research Organizations field, focusing on supporting emerging startups in women's health (FemTech), medical devices, and innovations in the biotech sector.
Visit us at PQE Group: Home - PQE Group , and follow PQE Group on LinkedIn, Instagram and Facebook
Learn more about Project-COMFORT: Home – Project-COMFORT, and follow us on LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20260127299159/en/
Contacts
PQE Group Press Office | Contacts: press@pqegroup.com
PQE Global
Debra J. Kaufmann
d.kaufmann@pqegroup.com
Mobile Phone – US : +240-704-0550
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press Release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On the demand side, with smart meter integration, Predict+ models each meter individually and performs extensive calculations on actual, historical, and average data to acc
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press Release
Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press Release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press Release
Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duration while maintaining flexible, up to once-monthly dosing for patients (every three or four weeks for PID). The TAK-881-3001 clinical trial ev
Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 12:00:00 CEST | Press Release
Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles the range and resolution of its lidar over the prior generation, adds native-color sensing, and is designed for functional safety. Based on patented Ouster Silicon with embedded Fujifilm color science, the L4 chip results in exquisite color data and hardware-enabled HDR. It boasts 42.9 GMACs of p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom